INTRODUCTION: The development of trastuzumab, a HER-2/neu targeted monoclonal antibody resulted in significant improvements in clinical response and survival in HER-2/neu gene amplified group of patients. Thus, accurate assessment of HER-2/neu status becomes critical. Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC) are the most commonly used methods for this purpose and specific recommendations exist with regard to the concordance to be observed between the two tests. AIM: Here, we report and evaluate the concordance rate between FISH and IHC for HER-2/neu status in breast cancer specimens. MATERIALS AND METHODS: Archival paraffin blocks of tumour tissue from 450 patients of breast cancer were analyzed for Her-2/neu status using FISH and IHC. RESULTS: There was a highly significant concordance between the results of FISH and IHC assays in HER-2/neu status assessment in invasive breast cancer cases. There were inverse associations between the expression of Oestrogen Receptors/Progesterone Receptors (ER/PR) and HER-2/neu amplification. CONCLUSION: Although, IHC gave significant concordant results with FISH in determining HER-2/neu status, its subjective grading system precludes its use as a gold standard. FISH should always be used to determine true gene amplification when the IHC results are equivocal.
INTRODUCTION: The development of trastuzumab, a HER-2/neu targeted monoclonal antibody resulted in significant improvements in clinical response and survival in HER-2/neu gene amplified group of patients. Thus, accurate assessment of HER-2/neu status becomes critical. Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC) are the most commonly used methods for this purpose and specific recommendations exist with regard to the concordance to be observed between the two tests. AIM: Here, we report and evaluate the concordance rate between FISH and IHC for HER-2/neu status in breast cancer specimens. MATERIALS AND METHODS: Archival paraffin blocks of tumour tissue from 450 patients of breast cancer were analyzed for Her-2/neu status using FISH and IHC. RESULTS: There was a highly significant concordance between the results of FISH and IHC assays in HER-2/neu status assessment in invasive breast cancer cases. There were inverse associations between the expression of Oestrogen Receptors/Progesterone Receptors (ER/PR) and HER-2/neu amplification. CONCLUSION: Although, IHC gave significant concordant results with FISH in determining HER-2/neu status, its subjective grading system precludes its use as a gold standard. FISH should always be used to determine true gene amplification when the IHC results are equivocal.
Authors: Abeer Alqaisi; Li Chen; Edward Romond; Mara Chambers; Mark Stevens; Grace Pasley; Mukta Awasthi; Suleiman Massarweh Journal: Breast Cancer Res Treat Date: 2014-09-26 Impact factor: 4.872
Authors: Erinn Downs-Kelly; Brian J Yoder; Mark Stoler; Raymond R Tubbs; Marek Skacel; Thomas Grogan; Patrick Roche; David G Hicks Journal: Am J Surg Pathol Date: 2005-09 Impact factor: 6.394
Authors: Kenneth Villman; Johanna Sjöström; Reino Heikkilä; Ragnar Hultborn; Per Malmström; Nils-Olof Bengtsson; Martin Söderberg; Eero Saksela; Carl Blomqvist Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: Sally Agersborg; Christopher Mixon; Thanh Nguyen; Sramila Aithal; Sucha Sudarsanam; Forrest Blocker; Lawrence Weiss; Robert Gasparini; Shiping Jiang; Wayne Chen; Gregory Hess; Maher Albitar Journal: Breast Cancer Res Treat Date: 2018-03-22 Impact factor: 4.872
Authors: Eline Boon; Miranda Bel; Wim van Boxtel; Winette T A van der Graaf; Robert J J van Es; Simone E J Eerenstein; Robert J Baatenburg de Jong; Michiel W M van den Brekel; Lilly-Ann van der Velden; Max J H Witjes; Ann Hoeben; Stefan M Willems; Elisabeth Bloemena; Laura A Smit; Sjoukje F Oosting; Marianne A Jonker; Uta E Flucke; Carla M L van Herpen Journal: Int J Cancer Date: 2018-03-23 Impact factor: 7.396